Modifying Pharmacokinetic Properties of the Gram-Negative Bacteria Targeting Endolysin ML06 Without Affecting Antibacterial Activity
International Journal of Molecular Sciences · 04.05.2025 · 26 (9) · 4376
DOI: 10.3390/ijms26094376 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.05.2025. Verfasst von Nataliia P Antonova und 6 weiteren Autor:innen. Beteiligte Einrichtung: N. F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Endopeptidases, Gram-Negative Bacteria. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
With the rise of antibiotic resistance, there is a need for innovative drugs with alternative mechanisms of action. Endolysins meet most of the requirements, but are limited for parenteral use due to their short blood circulation time. In this article, a number of modifications to the ML06-engineered, lysin-targeting Gram-negative bacteria are proposed to improve its pharmacokinetic parameters. Genetic modification with albumin-binding and dimerization domains ranging from 11–12 aa to 45 aa at both the C- and N-termini has resulted in six enzymes that do not exhibit critically reduced antibacterial properties in vitro, and in the case of the ABP1 modification, an improved antibacterial rate and spectra of enzymes. The ML06-ABP1, ML06-ABP2, and HDD-ML06 modifications also retained activity in blood serum and significantly increased serum stability. A pharmacokinetic study of the three modifications in mice showed that ML06-ABP2 and HDD-ML06 have a prolonged half-life compared to the ML06 half-life. In addition, the serum Cmax concentration for HDD-ML06 (22.2 μg/mL) was significantly increased compared to ML06 (Cmax < 5 μg/mL). Our results allow for a comparison of the different types of modifications that are useful in the development of parenteral antibacterials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- N. F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
- Department of Medical Genetics, Federal State Autonomous Educational Institution of Higher Education I M Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov Unive…
ORCID-Profile: Nataliia P Antonova, Daria V Vasina, Evgeny V Usachev
Förderung
- Russian Science Foundation
Zitieren
APA
Antonova, N. P., Abdullaeva, S. D., Vasina, D. V., Grigoriev, I. V., Usachev, E. V., Usacheva, O. V., & Gushchin, V. A. (2025). Modifying Pharmacokinetic Properties of the Gram-Negative Bacteria Targeting Endolysin ML06 Without Affecting Antibacterial Activity. International Journal of Molecular Sciences, 26(9), 4376. https://doi.org/10.3390/ijms26094376
Vancouver
Antonova NP, Abdullaeva SD, Vasina DV, Grigoriev IV, Usachev EV, Usacheva OV, et al. Modifying Pharmacokinetic Properties of the Gram-Negative Bacteria Targeting Endolysin ML06 Without Affecting Antibacterial Activity. International Journal of Molecular Sciences. 2025;26(9):4376. doi:10.3390/ijms26094376
BibTeX
@article{Antonova2025,
author = {Antonova, Nataliia P and Abdullaeva, Sofia D and Vasina, Daria V and Grigoriev, Igor V and Usachev, Evgeny V and Usacheva, Olga V and Gushchin, Vladimir A},
title = {Modifying Pharmacokinetic Properties of the Gram-Negative Bacteria Targeting Endolysin ML06 Without Affecting Antibacterial Activity},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {9},
pages = {4376},
doi = {10.3390/ijms26094376}
}
EUVIMED